Network Meta-Analysis Reveals Comparable Efficacy Among Leading Chronic Constipation Treatments
核心洞察
A comprehensive systematic review and network meta-analysis evaluated 21 randomized controlled trials involving 9,189 patients with chronic idiopathic constipation (搜索).
Multiple treatments including bisacodyl, sodium picosulfate, prucalopride, and velusetrag demonstrated superior efficacy compared to placebo in achieving complete spontaneous bowel movements.
While no single drug emerged as clearly superior for primary endpoints, bisacodyl showed potential advantages in improving weekly spontaneous bowel movement frequency.
A systematic review and network meta-analysis has provided new insights into the comparative efficacy of pharmacological treatments for chronic idiopathic constipation (搜索) (CIC), evaluating data from 21 randomized controlled trials encompassing 9,189 patients.
The comprehensive analysis, published in Gut, examined multiple therapeutic options including established treatments and newer agents. The study focused on key efficacy measures, particularly the achievement of three or more complete spontaneous bowel movements (CSBM) per week and improvements from baseline.
Treatment Efficacy Findings
Several medications demonstrated significant efficacy compared to placebo. Bisacodyl, sodium picosulfate, prucalopride, and velusetrag all showed superior results in achieving the primary endpoint of three or more complete spontaneous bowel movements per week. However, when compared against each other through network meta-analysis, no single treatment emerged as definitively superior for the primary endpoints.
Secondary Endpoint Analysis
In examining secondary outcomes, bisacodyl demonstrated particularly promising results. The medication appeared to outperform other treatments in improving the baseline number of spontaneous bowel movements per week, though this finding must be interpreted within the context of the overall analysis.
Study Methodology and Scope
The research team conducted an extensive literature search spanning multiple databases from their inception through May 2015. They specifically focused on Phase IIB and Phase III randomized, placebo-controlled trials lasting four weeks or longer. All included studies enrolled adult patients meeting Rome II or III criteria for functional constipation.
The analysis encompassed various treatment options:
- 9 trials of prucalopride
- 3 trials each of lubiprostone and linaclotide
- 2 trials of tegaserod
- Single trials of velusetrag, elobixibat, bisacodyl, and sodium picosulfate
Clinical Implications
These findings provide valuable guidance for healthcare providers in selecting appropriate treatments for CIC patients. The comparable efficacy among different therapeutic options suggests that treatment choices may be individualized based on patient-specific factors, tolerability, and cost considerations.
The research highlights the robust evidence supporting multiple treatment options for CIC, while also indicating areas where additional comparative studies might be beneficial. This information is particularly relevant given the significant impact of CIC on patient quality of life and healthcare resource utilization.